9 Meters Biopharma, Inc.

North Carolina State University

Sandeep Laumas

Jay Madan

Balasingham Radhakrishnan

Anthony Blikslager

Christopher Prior

The present invention provides Larazotide derivative compositions that resist protease degradation, and in various embodiments, do not demonstrate an inverse dose response, and/or can be delivered at higher doses without loss of potency or efficacy, thereby allowing improved therapy and more desirable dosing schedules.

Compounds and methods for treating tight junction permeabtility

The present invention provides compositions and methods for treating a patient having cancer, as well as methods for potentiating an immune checkpoint inhibitor therapy. The methods comprise administering larazotide or a derivative thereof such as (d)-larazotide to a subject in need, including subjects undergoing checkpoint inhibitor therapy, and subjects scheduled to undergo immune checkpoint inhibitor therapy.

Treatment of cancer with larazotide derivatives in combination with immune checkpoint inhibitors

The present invention provides methods for treating disorders associated with intestinal barrier dysfunction and increased intestinal permeability. The invention involves administering an effective amount larazotide or a larazotide derivative to a subject or a patient in need thereof.

Growing community of inventors

Raleigh, NC, United States of America

Sandeep Laumas